Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL
The purpose of this study is to evaluate the efficacy and safety of Basiliximab in combination with pegaspargase in the treatment of relapsed/refractory NK/T-cell lymphoma.
Extranodal NK/T-cell Lymphoma
DRUG: Basiliximab|DRUG: Pegaspargase
complete response rate, evaluated by PET-CT scan or MRI, according to 2014 Lugano criteria for lymphoma, up to 15 weeks±1 week from start of treatment
overall response rate, evaluated by PET-CT scan or MRI, according to 2014 Lugano criteria for lymphoma, up to 15 weeks±1 week from start of treatment|one year progression free survival rate, Progression free survival was caculated from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
The investigators previously found that CD25 was elevated in patients who were resistant to chemotherapy, and CD25 can mediate resistance, which can be reversed by targeting CD25 therapy. Thus, the purpose of this study is to evaluate the efficacy and safety of Basiliximab in combination with pegaspargase in the treatment of relapsed/refractory NK/T-cell lymphoma.